The stock of Coherus Biosciences Inc (NASDAQ:CHRS) is a huge mover today! About 392,885 shares traded hands. Coherus Biosciences Inc (NASDAQ:CHRS) has risen 21.91% since April 8, 2016 and is uptrending. It has outperformed by 16.26% the S&P500.
The move comes after 6 months positive chart setup for the $1.37 billion company. It was reported on Nov, 10 by Barchart.com. We have $35.47 PT which if reached, will make NASDAQ:CHRS worth $356.20M more.
Analysts await Coherus Biosciences Inc (NASDAQ:CHRS) to report earnings on November, 14. They expect $-1.71 earnings per share, up 8.06% or $0.15 from last year’s $-1.86 per share. After $-1.72 actual earnings per share reported by Coherus Biosciences Inc for the previous quarter, Wall Street now forecasts -0.58% EPS growth.
Coherus Biosciences Inc (NASDAQ:CHRS) Ratings Coverage
Out of 6 analysts covering Coherus Biosciences (NASDAQ:CHRS), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Coherus Biosciences has been the topic of 6 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Maxim Group given on Wednesday, September 7. The stock has “Outperform” rating given by Credit Suisse on Wednesday, January 20. Robert W. Baird initiated the shares of CHRS in a report on Wednesday, October 19 with “Outperform” rating. The rating was initiated by Barclays Capital on Monday, November 23 with “Overweight”. The company was upgraded on Thursday, September 3 by Zacks. As per Wednesday, July 27, the company rating was initiated by Citigroup.
According to Zacks Investment Research, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.”
Insitutional Activity: The institutional sentiment increased to 3.32 in 2016 Q2. Its up 1.99, from 1.33 in 2016Q1. The ratio increased, as 10 funds sold all Coherus Biosciences Inc shares owned while 9 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 49.39 million shares or 180.37% more from 17.62 million shares in 2016Q1.
Dekabank Deutsche Girozentrale holds 0% or 22,400 shares in its portfolio. Royal National Bank & Trust Of Canada holds 600 shares or 0% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Rock Springs Capital Limited Partnership holds 0.5% or 400,000 shares in its portfolio. Lombard Odier Asset Mngmt (Switzerland) holds 0.25% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS) for 109,664 shares. Teacher Retirement System Of Texas reported 3,260 shares or 0% of all its holdings. Credit Suisse Ag last reported 0% of its portfolio in the stock. Springbok Capital Management Limited Liability Com accumulated 2,900 shares or 0.01% of the stock. Cormorant Asset Lc last reported 1.38% of its portfolio in the stock. Jefferies Gp Ltd Liability Corp has 0% invested in the company for 13,651 shares. Moreover, Franklin Resources has 0% invested in Coherus Biosciences Inc (NASDAQ:CHRS) for 25,000 shares. Oxford Asset Management holds 43,157 shares or 0.03% of its portfolio. Commerzbank Aktiengesellschaft Fi accumulated 0% or 30,013 shares. Voya Investment Management Ltd Company accumulated 13,314 shares or 0% of the stock. State Board Of Administration Of Florida Retirement System has 14,279 shares for 0% of their US portfolio.
More news for Coherus Biosciences Inc (NASDAQ:CHRS) were recently published by: Fool.com, which released: “Why Coherus BioSciences, Inc. Is Dropping Today” on November 07, 2016. Globenewswire.com‘s article titled: “Coherus BioSciences to Report Third Quarter 2016 Financial Results on November 9th” and published on November 01, 2016 is yet another important article.
CHRS Company Profile
Coherus BioSciences, Inc., incorporated on September 29, 2010, is a late-stage clinical biologics platform company. The Firm is focused on the global biosimilar market. The Firm operates through developing and commercializing biosimilar products segment. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.